# Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study

Study · id `cardio:ct-nct07380919` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07380919](<https://clinicaltrials.gov/study/NCT07380919>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07380919

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07380919. Randomized; no masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2026-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07380919, source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)
- Planned start: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07380919, source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)
- Primary completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07380919, source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)
- Completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07380919, source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT07380919, source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07380919-2026-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study
- Acronym: INaMICRON
- Condition: STEMI (ST Elevation MI)
- Intervention (Drug): Ranolazine
- Lead sponsor: Federico II University
- Lead sponsor class: OTHER
- Collaborator: Università Magna Grecia, Catanzaro
- Collaborator class: UNKNOWN
- Collaborator: Santa Maria Goretti Hospital, Latina
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Federico II University (`cardio:org-federico-ii-university`)

## Provenance

Content hash: 19cce98f459d83ed66866552c1fbd6fecaf4dba3b424a8f8a6861af4926d7b78
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
